NVS : Summary for Novartis AG - Yahoo Finance

U.S. Markets open in 1 hr 17 mins

Novartis AG (NVS)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
74.85+0.02 (+0.03%)
At close: 4:02PM EDT
People also watch
GSKSNYAZNLLYABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close74.83
Open74.86
Bid73.00 x 500
Ask77.77 x 100
Day's Range74.82 - 75.11
52 Week Range66.93 - 83.58
Volume1,822,925
Avg. Volume3,376,509
Market Cap175.37B
Beta0.71
PE Ratio (TTM)26.73
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.75 (3.67%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist37 minutes ago

    Why Entresto Could Become Key Growth Driver for Novartis in 2017

    Novartis (NVS) expects modest prescription growth for its heart failure drug, Entresto, in 1Q17.

  • Market Realist37 minutes ago

    Performance of GlaxoSmithKline’s Vaccines Business in 2016

    GSK's Vaccines business reported growth of 14% to ~4.6 billion pounds in 2016.

  • Reuters7 hours ago

    Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

    Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker's CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia. The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient's own T-cells being altered in the lab to help the immune system find and kill cancer cells before being re-infused into the patient.